
Home » Abbott Targets Amneal in Latest Fight Over Generic Niaspan
Abbott Targets Amneal in Latest Fight Over Generic Niaspan
September 4, 2012
Abbott Laboratories’ AbbVie hit Amneal Pharmaceuticals with a patent suit in Delaware Federal Court, arguing that Amneal has infringed a patent covering its cholesterol medication, Niaspan.
Law360
Law360
Upcoming Events
-
19Jan
-
21Jan
-
26Jan
-
27Jan
-
27Jan
-
09Feb